Your session is about to expire
← Back to Search
Tetracycline Antibiotic
Minocycline in MS: Confirmation of Benefit (MS Trial)
Phase 3
Waitlist Available
Led By Luanne Metz, MD,FRCPC
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3,6,12,and 24 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial tests if minocycline, an antibiotic that helps control the immune system, can delay or prevent multiple sclerosis in adults who show early signs of the disease. Minocycline works by reducing brain inflammation and has been studied for its potential to treat multiple sclerosis due to its anti-inflammatory and neuroprotective properties.
Eligible Conditions
- Multiple Sclerosis
- Clinically Isolated Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3,6,12,and 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3,6,12,and 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria
Secondary study objectives
Proportion of participants diagnosed with multiple sclerosis according to the 2005 McDonald Criteria
The proportion of participants with no evidence of disease activity (NEDA)
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: MinocyclineExperimental Treatment1 Intervention
Minocycline 100 mg oral twice daily for up to 24 month
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minocycline
FDA approved
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
810 Previous Clinical Trials
886,285 Total Patients Enrolled
9 Trials studying Multiple Sclerosis
407 Patients Enrolled for Multiple Sclerosis
Multiple Sclerosis Society of CanadaOTHER
15 Previous Clinical Trials
968 Total Patients Enrolled
15 Trials studying Multiple Sclerosis
968 Patients Enrolled for Multiple Sclerosis
Hotchkiss Brain Institute, University of CalgaryOTHER
11 Previous Clinical Trials
2,423 Total Patients Enrolled
Luanne Metz, MD,FRCPCPrincipal InvestigatorUniversity of Calgary